Abstract:Introduction Escherichia coli l -asparaginase (EcA), an integral part of multi-agent chemotherapy protocols of acute lymphoblastic leukemia (ALL), is constrained by safety concerns and the development of anti-asparaginase antibodies. Novel variants with better pharmacological properties are desirable. Methods Thousands of novel EcA variants were constructed using protein engineering approach. After preliminary screening, two mutants, KHY-17 and KHYW-17 were selected for further development. The variants were characterized for asparaginase activity, glutaminase activity, cytotoxicity and antigenicity in vitro. Immunogenicity, pharmacokinetics, safety and efficacy were tested in vivo. Binding of the variants to pre-existing antibodies in primary and relapsed ALL patients' samples was evaluated. Results Both variants showed similar asparaginase activity but approximately 24-fold reduced glutaminase activity compared to wild-type EcA (WT). Cytotoxicity against Reh cells was significantly higher with the mutants, although not toxic to human PBMCs than WT. The mutants showed approximately 3-fold lower IgG and IgM production compared to WT. Pharmacokinetic study in BALB/c mice showed longer half-life of the mutants (KHY-17- 267.28±9.74; KHYW-17- 167.41±14.4) compared to WT (103.24±18). Single and repeat-doses showed no toxicity up to 2000 IU/kg and 1600 IU/kg respectively. Efficacy in ALL xenograft mouse model showed 80–90 % reduction of leukemic cells with mutants compared to 40 % with WT. Consequently, survival was 90 % in each mutant group compared to 10 % with WT. KHYW-17 showed over 2-fold lower binding to pre-existing anti-asparaginase antibodies from ALL patients treated with l -asparaginase. Conclusion EcA variants demonstrated better pharmacological properties compared to WT that makes them good candidates for further development.

In vitro and in silico analysis unravelled clinically desirable attributes of Bacillus altitudinis L-asparaginase

Isolation of asparaginase-producing microorganisms and evaluation of the enzymatic antitumor activity

Studies on the Recombinant Production in E. Coli and Characterization of Pharmaceutically Important Thermostable L-Asparaginase from Geobacillus Thermodenitrificans

Production of highly cytotoxic and low immunogenic L-asparaginase from Stenotrophomonas maltophilia EMCC2297

Production of a Novel Marine Pseudomonas aeruginosa Recombinant L-Asparaginase: Insight on the Structure and Biochemical Characterization

Aliivibrio fischeri L-Asparaginase production by engineered Bacillus subtilis: a potential new biopharmaceutical

Studies on the Recombinant Production and Anticancer Activity of Thermostable L- Asparaginase I from Pyrococcus Abyssi.

Production and Anticancer Activity of an L-Asparaginase from Bacillus licheniformis Isolated from the Red Sea, Saudi Arabia

Rational Engineering and Insight for a L-glutaminase Activity Reduced Type II L-asparaginase from Bacillus Licheniformis and Its Antileukemic Activity in Vitro.

Purification and characterisation of a novel broad spectrum anti-tumor L-glutaminase enzyme from marine Bacillus subtilis strain JK-79

Isolation, Identification, and Characterization of L-asparaginase-Producing Human Commensal Bacterial Strains: A Promising Next-Gen Probiotics

Biotechnological production and practical application of L-asparaginase enzyme

Biochemical characterization of glutaminase-free L-asparaginases from Himalayan Pseudomonas and Rahnella spp. for acrylamide mitigation

Isolation and characterization of fungi producing L-Asparaginase with reduced L-glutaminase activity from soil samples

Expression, characterization and cytotoxicity of recombinant l-asparaginase II from Salmonella paratyphi cloned in Escherichia coli

Cloning, expression, and characterization of a novel thermo-acidophilic l-asparaginase of Pseudomonas aeruginosa CSPS4

Enhanced production of glutaminase free L-asparaginase II by Bacillus subtilis WB800N through media optimization

A Structural In Silico Analysis of the Immunogenicity of L-Asparaginase from Penicillium cerradense

Bio Potential of a Marine fungus Sarocladium kiliense in Fermentative production of Anti-cancer Enzyme L-Asparaginase using Solid Waste substrates and Evaluation of its Cytotoxic Role against Jurkat J6 and PA1 Cell lines

What makes a good new therapeutic l-asparaginase?

Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia